Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Highlight
- Early rhythm control therapy significantly reduces cardiovascular events in patients with early atrial fibrillation.
- Diabetes and obesity do not diminish the benefits or safety of early rhythm control therapy in this population.
- Patients with obesity and diabetes presented with higher cardiovascular risk profiles but still benefited similarly from intervention compared to those without these conditions.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.